 Connection
Charles Daley to Patient Reported Outcome Measures
This is a "connection" page, showing publications Charles Daley has written about Patient Reported Outcome Measures.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.849 |
|
|
|
-
Mange KC, Serrano D, Hassan M, Nevoret ML, Yuen DW, McManus S, Podger L, Barnes B, Daley CL. Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies. J Patient Rep Outcomes. 2025 Oct 16; 9(1):119.
Score: 0.675
-
Daley CL, van Ingen J, Chalmers JD, Flume PA, Griffith DE, Hasegawa N, Morimoto K, Winthrop KL, Sheu CC, Avsar K, Andrisani D, Codecasa LR, Terschlüsen E, May D, Yuen DW, Wu P, Hassan M, Nevoret ML, Mange K. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial. Ann Am Thorac Soc. 2026 Apr 01; 23(4):536-547.
Score: 0.174
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|